期刊文献+

益气温阳汤联合激素治疗对免疫性血小板减少性紫癜患者免疫功能及血小板计数的影响

Effect of Yiqi Wenyang Decoction Combined with Hormone Therapy on Immune Function and Platelet Count in Patients with Immune Thrombocytopenic Purpura
在线阅读 下载PDF
导出
摘要 目的分析益气温阳汤联合激素治疗免疫性血小板减少性紫癜(ITP)的效果。方法选取2017年8月—2022年8月本院收治的78例ITP患者为研究对象,按随机数字表法分为两组,每组39例。对照组采用激素治疗,观察组在此基础上采用益气温阳汤治疗,均连续治疗3个月。对比两组患者的临床疗效、免疫功能、血小板计数(PLT)及不良反应发生情况。结果观察组的治疗总有效率为94.87%,高于对照组的79.49%,差异有统计学意义(P<0.05)。治疗后观察组的PLT开始上升时间、PLT恢复正常时间分别为(3.21±0.48)d、(8.35±1.01)d,均短于对照组的(5.39±0.78)d、(9.96±1.84)d,组间差异有统计学意义(P<0.05)。治疗后,观察组的CD3^(+)、CD4^(+)、PLT水平分别为(76.31±4.49)%、(41.48±3.75)%、(95.96±6.35)×10^(9)/L,均高于对照组的(70.26±3.57)%、(36.25±3.09)%、(80.31±4.36)×10^(9)/L,CD8^(+)水平为(26.31±1.53)%,低于对照组的(29.77±1.84)%,组间差异有统计学意义(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论益气温阳汤联合激素治疗ITP的效果显著,可改善患者免疫功能,促进PLT恢复,且无严重不良反应,临床应用价值较高,可进行大力推广。 Objective To analyze the effects of Yiqi Wenyang Decoction combined with hormone on immune thrombocytopenic purpura(ITP).Methods 78 patients with ITP admitted to the hospital from August 2017 to August 2022 were selected as the research objects and were divided into two groups according to random number table method,with 39 cases in each group.The control group was treated with hormone therapy,and the observation group was treated with Yiqi Wenyang Decoction on this basis.Both groups were treated continuously for 3 months.The clinical efficacy,immune function,platelet count(PLT)and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 94.87%,higher than 79.49%of the control group,the difference was statistically significant(P<0.05).After treatment,the time of PLT beginning to rise and the time of PLT returning to normal in the observation group were(3.21±0.48)d and(8.35±1.01)d,respectively,which were shorter than(5.39±0.78)d and(9.96±1.84)d in the control group,and the differences between the groups were statistically significant(P<0.05).After treatment,the levels of CD3^(+),CD4^(+)and PLT in the observation group were(76.31±4.49)%,(41.48±3.75)%,(95.96±6.35)×10^(9)/L,respectively,which were higher than(70.26±3.57)%,(36.25±3.09)%,(80.31±4.36)×10^(9)/L in the control group,while the CD8^(+)level was(26.31±1.53)%,lower than(29.77±1.84)%in the control group,and the differences between the groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Yiqi Wenyang Decoction combined with hormone therapy for ITP has significant effect,which can improve the immune function of patients and promote the recovery of PLT without serious adverse reactions.It has high clinical application value and can be vigorously promoted.
作者 范金兰 张敏 FAN Jinlan;ZHANG Min(Department of Hematology,Heze Hospital of Traditional Chinese Medicine,Heze Shandong,274000,China)
出处 《反射疗法与康复医学》 2023年第11期1-3,7,共4页 Reflexology And Rehabilitation Medicine
关键词 免疫性血小板减少性紫癜 益气温阳汤 激素 免疫功能 血小板计数 Immune thrombocytopenic purpura Yiqi Wenyang Decoction Hormones Immune function Platelet count
作者简介 范金兰(1984-),女,安徽宿州人,硕士研究生,主治医师,研究方向:常见血液病的中医诊治。
  • 相关文献

二级参考文献100

  • 1朱小勤,陈珮,邱仲川,黄中迪,赵琳,胡晓莹,瞿玮颖,陆颖佳,封舟.紫癜合剂对原发免疫性血小板减少症患者Treg/Th17细胞平衡的影响[J].上海中医药杂志,2020,54(S01):86-89. 被引量:4
  • 2吕学文,刘仿,伍昌林.Foxp3基因表达与CD4^+CD_(25)^+调节性T细胞在急性特发性血小板减少性紫癜发病中的作用[J].实用儿科临床杂志,2007,22(3):188-190. 被引量:18
  • 3ProvanD, StasiR, NewlandAC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia[J]. Blood,2010,115(2):168-186.
  • 4NeunertC, LimW, CrowtherM, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J]. Blood,2011,117(16):4190-4207.
  • 5British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy[J]. Br J Haematol,2003,120(4):574-596. doi:10.1046/j.1365-2141.2003.04131.x.
  • 6WeiY, JiXB, WangYW, et al. High-dose dexamethasone versus prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial[J]. Blood,2016,127(3):296-302. doi:10.1182/blood-2015-07-659656.
  • 7WangS, YangR, ZouP, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia[J]. Int J Hematol,2012,96(2):222-228. doi:10.1007/s12185-012-1124-8.
  • 8BusselJB, ChengG, SalehMN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura[J]. N Engl J Med,2007,357(22):2237-2247. doi:10.1056/NEJMoa073275.
  • 9BusselJB, ProvanD, ShamsiT, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, doubleblind, placebo-controlled trial[J]. Lancet,2009,373(9664):641-648. doi:10.1016/S0140-6736(09)60402-5.
  • 10ChengG, SalehMN, MarcherC, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study[J]. Lancet,2011,377(9763):393-402. doi:10.1016/S0140-6736(10)60959-2.

共引文献470

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部